Skip to content

Circles

G

Grace Therapeutics, Inc.

GRCE· Nasdaq

G

GRCEGrace Therapeutics, Inc.

GRCEGrace Therapeutics, Inc.·Earnings record

Q4 2019

Source filing unavailable

Next · Q1 2020

Q4 2019 · —

Revenue—

Net Income

-$39.37M

no prior Q4 2018 on file

EPS, diluted—

Operating Cash Flow-$24,787,000—

Free Cash Flowderived-$25,321,000—

Same quarter

no prior Q4 2018 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Filing lag

Quarterly history

Q4 ’19Q1 ’20 Q2 ’20 Q3 ’20 Q4 ’20 Q1 ’21 Q2 ’21 Q3 ’21 Q4 ’21^d…

Grace Therapeutics, Inc. · CIK 1444192 · Engraved from SEC EDGAR

Thaler ResearchEngraved from SEC EDGAR© 2026 Thaler. All rights reserved.Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Platform

Using AI API SDKs CLI

Research

News Listen Earnings Insiders Holders Compare Metrics

Screener Watchlists Pies Notes Your companies

Learn

Thaler

Thaler Agent Promise Provenance Circles Account Terms Privacy